EMEA-000366-PIP04-12

Key facts

Invented name
Humira
Active substance
adalimumab
Therapeutic area
Dermatology
Decision number
P/0121/2013
PIP number
EMEA-000366-PIP04-12
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
Treatment of hidradenitis suppurativa
Route(s) of administration
Subcutaneous use
Contact for public enquiries
AbbVie Ltd

Unied Kingdom
E-mail: paediatricteam@abbvie.com
Tel. +44 (0)791 988 1614
Fax +44 (0)1628 672 566

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Compliance procedure number
EMEA-C-000366-PIP04-12
Compliance opinion date
01/04/2016
Compliance outcome
positive

Decision

How useful was this page?

Add your rating